Thrombotic thrombocytopenic purpura (TTP) 
Introduction

Thrombotic thrombocytopenic purpura (TTP) is a potentially fatal disorder characterized by microangiopathic hemolytic anemia (MAHA) and thrombocytopenia, and it is often associated with neurological dysfunction, renal failure, and fever (1). Idiopathic and congenital TTP have also been reported. Most patients have underlying factors and conditions such as drugs, autoimmune diseases, infections, post-stem cell transplantation, or pregnancy (2). Deficiency of a disintegrin-like metalloprotease with thrombospondin type 1 motifs 13 (ADAMTS13), a von Willebrand factor-cleaving protease, has been recently reported to be the cause of TTP (1). For assessing TTP, it is critical to exclude other differential diagnoses. The evaluation of pregnant women is
particularly difficult because the characteristic signs of TTP may also occur in patients with severe preeclampsia, eclampsia, and hemolysis, elevated liver enzyme levels, and a low platelet count (HELLP) syndrome (2 T a b l e 1 . L a b o r a t o r y F i n d i n g s 
